Loading Events

« All Events

  • This event has passed.

Bone, Reproductive and Urologic Drugs Advisory Committee

January 16

The committee will discuss biologics license application 761062, romosozumab injection, submitted by Amgen, for the proposed indication of treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant of other available osteoporosis therapy.


January 16
Event Category: